Virology Conference 2026

The  30th Edition of the International Conference on Virology  will be held on  January 19–20, 2026, in Vancouver, Canada . This prestigious event brings together leading virologists, researchers, healthcare professionals, industry experts, and academicians from around the globe to exchange knowledge, present research findings, and discuss the latest innovations in the field of virology.

The conference will serve as a premier platform to explore diverse aspects of viral biology, emerging viral infections, vaccine development, antiviral therapies, molecular virology, viral pathogenesis, and epidemiology. With a strong focus on global health challenges, it will address critical issues such as pandemic preparedness, zoonotic viruses, diagnostic advancements, and strategies for controlling viral diseases.

In addition to keynote lectures by eminent scientists, the conference will feature interactive sessions, panel discussions, poster presentations, and networking opportunities that encourage collaboration across disciplines. Attendees will have the chance to share their expertise, gain insights into groundbreaking research, and foster partnerships that drive progress in virology and public health.

Set against the backdrop of  Vancouver’s vibrant scientific and cultural environment , this edition promises to be an enriching experience for all participants. Whether you are an established researcher, an early-career scientist, a clinician, or an industry professional, the International Conference on Virology 2026 offers an invaluable opportunity to contribute to the advancement of viral research and its application to global healthcare.

Target Audience 

• Directors, Board Members, Presidents, Vice Presidents
• Deans and Head of the Departments
• Business Entrepreneurs and Industrialists
• Microbiologist
• Virologists
• Parasitologist
• Bacteriologist
• Pharmacists
• Epidemiologists
• Dermatologists
• Neurologist
• Ophthalmologist
• Cardiologist
• Infectious Diseases Researchers, Scientists, Faculties, Students
• Infectious Diseases Associations and Societies
• Medical Colleges, Hospitals & Labs
• Pharmaceutical Companies and Industries
• Medical devises Manufacturing Companies
• Drug Manufacturing Companies and Industries
• Laboratory Technicians and Diagnostic Companies

Sessions and Tracks

Track 1: Molecular and Cellular Virology 

Explore the fundamental mechanisms of virus replication, transcription, and translation within host cells. This track will highlight the latest findings on viral genome organization, protein interactions, host-virus signaling pathways, and the molecular basis of viral evolution.

Track 2: Emerging and Re-Emerging Viral Infections 

This session focuses on newly identified viruses as well as the resurgence of well-known viral diseases. Topics include Ebola, Zika, Nipah, Influenza variants, and SARS-CoV-2, along with the ecological and epidemiological factors driving viral emergence.

Track 3: Viral Pathogenesis and Host Immune Response 

Delve into how viruses invade host systems, evade immune defenses, and cause disease. Discussions will cover innate and adaptive immune responses, immune evasion strategies, and implications for therapeutic development.

Track 4: Vaccine Development and Immunization Strategies 

A dedicated track for breakthroughs in vaccine research, including mRNA technology, viral vector vaccines, next-generation universal vaccines, and global vaccination strategies to combat pandemics.

Track 5: Antiviral Therapeutics and Drug Discovery 

Learn about current and future antiviral therapies, drug resistance challenges, and innovative approaches such as RNA-based therapies, monoclonal antibodies, and host-targeted antivirals.

Track 6: Viral Genomics and Bioinformatics 

This session will focus on the role of next-generation sequencing, metagenomics, and computational virology in understanding viral diversity, outbreak tracing, and precision medicine.

Track 7: Clinical Virology and Diagnostics 

A practical track covering advances in point-of-care testing, molecular diagnostic techniques, serological assays, and biomarkers for early detection and clinical management of viral infections.

Track 8: Zoonotic Viruses and One Health Approach 

Discuss the interconnectedness of human, animal, and environmental health in preventing viral outbreaks. This session will emphasize zoonotic spillovers, wildlife reservoirs, and strategies for global health preparedness.

Track 9: Virology in Cancer and Gene Therapy 

Examine the role of oncoviruses in cancer development and the promising use of viral vectors in gene therapy, immunotherapy, and personalized medicine.

Track 10: Global Virology and Public Health Policy 

This closing track will address the socio-economic impact of viral diseases, public health strategies, surveillance systems, pandemic preparedness, and the role of international collaborations in combating viral threats.

Track 11: Parasitic Infectious Diseases

Parasitic infections caused by protozoa and helminths contribute to substantial morbidity and mortality, particularly in impoverished tropical areas. Control measures include public health interventions, access to clean water, and deworming programs to reduce the burden of parasitic diseases.

Track 12: Viral Infections

Viral infections, characterized by rapid onset and often short-lived symptoms, encompass a wide range of diseases, including influenza and viral hemorrhagic fever. Effective prevention strategies involve vaccination, antiviral medications, and public health measures such as isolation and hygiene practices. Ongoing research is essential to stay ahead of viral mutations and emerging infectious threats.

Track 13: Recent Outbreaks and their Control

Despite the availability of vaccines, preventable infectious diseases can still cause outbreaks. Understanding the factors contributing to these outbreaks is crucial for implementing effective control measures. Rapid response, vaccination campaigns, and public health interventions play pivotal roles in containing and preventing the spread of infectious diseases during outbreaks.

Track 14: Virology

Virology delves into the intricate world of viruses, exploring their structural composition, evolutionary dynamics, and pathogenic mechanisms. From elucidating host-virus interactions to harnessing viral agents for therapeutic purposes, this discipline navigates diverse facets of virological research, spanning from classification to therapeutic applications.

• Insights into viral structure and classification
• Diseases and host immune responses
• Cutting-edge molecular biology research

Track 15: Human Virology and Infectious Diseases

Human Virology intersects with the broader landscape of infectious diseases, encompassing pathogens like HIV, hepatitis B and C, and human papillomavirus (HPV). Addressing these infections demands concerted efforts in prevention, diagnosis, and treatment, with a focus on bolstering immune responses and curtailing disease transmission.

• Noteworthy human viral infections

Track 16: Vector Borne and Zoonotic Infectious Diseases

Vector Borne and Zoonotic Infectious Diseases present formidable challenges, often bridging the gap between animal hosts and human populations. From avian flu to malaria, these diseases underscore the intricate interplay between vectors, pathogens, and human susceptibility, necessitating multifaceted intervention strategies for disease control.

• Prominent vector borne and zoonotic diseases

Track 17: Food and Water Borne Diseases

Food and Water Borne Diseases epitomize the intersection between microbial contamination and human consumption. From travelers’ diarrhea to cholera, these ailments underscore the imperative of stringent food and water safety measures, mitigating the risk of gastrointestinal infections and their associated morbidities.

• Common food and water borne diseases

Track 18: Viral Oncology

Viral Oncology explores the intricate nexus between viral infections and oncogenic processes, elucidating the role of oncoviruses in cancer pathogenesis. From human oncoviruses to classification schemes, this field delves into the molecular mechanisms underpinning viral-induced malignancies, paving the way for innovative therapeutic strategies.

• Human oncoviruses and their implications

Track 19: Bacterial and Viral Vaccines

Bacterial and Viral Vaccines epitomize the cornerstone of preventative medicine, harnessing the immune system to confer protection against infectious agents. From pneumococcal to polio vaccines, these immunological interventions underscore the pivotal role of vaccination in disease eradication and public health promotion.

Market Analysis

The virology market is experiencing steady global growth, projected to expand at around 5% CAGR through 2035, driven by advances in antiviral drugs, diagnostics, and vaccines. The United States dominates with over 40% global share and a faster growth rate (\~6.6% CAGR), supported by strong R\&D infrastructure, significant pharmaceutical investment, and pandemic-preparedness initiatives. Canada, though smaller, shows consistent expansion within its infectious disease therapeutics market (USD 7.95 billion in 2024, CAGR \~3.8%), where viral infections form the largest segment, backed by public health programs and biotech activity. Europe, holding roughly 30% of the global virology market, is the second-largest region, with countries like Germany and the UK driving growth (4–5% CAGR) through robust healthcare systems, government-backed disease prevention efforts, and expanding virology diagnostics (USD 1.3 billion in 2024, CAGR \~6.1%). Collectively, these regions form the core of the virology industry, with the U.S. leading innovation, Europe advancing healthcare integration, and Canada contributing steadily to therapeutic development.